Cart
sales@molnova.com
Emavusertib
CAS No. 1801344-14-8
Emavusertib( CA-4948 )
Catalog No. M23815 CAS No. 1801344-14-8
Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 72 | In Stock |
|
| 2MG | 42 | In Stock |
|
| 5MG | 67 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 25MG | 169 | In Stock |
|
| 50MG | 305 | In Stock |
|
| 100MG | 524 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEmavusertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEmavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
-
DescriptionEmavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
-
In Vitro——
-
In VivoAnimal Model:Mice bearing OCI-LY10 tumorsDosage:25, 50, or 150 mg/kg (once daily), 12.5, 25, or 50 mg/kg (twice daily)Administration:Orally, once daily or twice daily, for 14 consecutive days Result:Induced tumor growth inhibition. Emavusertib administered as a twice-daily divided dose was equivalent to the corresponding once-daily dose with regards to antitumor activity, i.e., 12.5 mg/kg BID versus 25 mg/kg QD.
-
SynonymsCA-4948
-
PathwayAngiogenesis
-
TargetFLT
-
RecptorFLT3|IRAK4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1801344-14-8
-
Formula Weight491.5
-
Molecular FormulaC24H25N7O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:27.78 mg/mL (56.52 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)
-
SMILESCC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.
molnova catalog
related products
-
Pacritinib
Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.
-
BGB-102
BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.
-
4SC-203
4SC-203 is a multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs).
